HIV 1 News and Research

RSS

Genetic Immunity announces first patient dosed in trial with DermaVir patch for HIV

Genetic Immunity, a US/Hungarian clinical-stage company focused on development of nanomedicines for targeted immune amplification, today announced it has treated the first subject in a Phase II clinical study to evaluate DermaVir Patch.

13 Nov 2008

Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections

Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.

13 Nov 2008

100,000 saved from dying of tuberculosis

Asma Elsony led the tuberculosis programme in Sudan at the same time as she took her doctoral degree under the supervision of Professor Gunnar Bjune of the Department of General Practice and Community Medicine, University of Oslo in Norway.

13 Nov 2008

Analyses of Merck's HIV vaccine 'Step' study

Results from the Step study, a test-of-concept efficacy study of a Merck & Co., Inc. HIV vaccine candidate, were published online in two papers in The Lancet.

12 Nov 2008

Discovery of unique approach for delivering drugs to the brain - potential for Alzheimer's and stroke

Saint Louis University researchers have identified a novel way of getting a potential treatment for Alzheimer's disease and stroke into the brain where it can do its work.

12 Nov 2008

Impact of the global financial and economic crisis on health

We face a severe financial crisis of unprecedented dimensions in a world that has never before been so closely connected and interdependent. The consequences are global. The situation is volatile. The current financial crisis is rapidly becoming an economic crisis and threatens to become a social crisis in many countries.

12 Nov 2008

Without enzyme, biological reaction essential to life takes 2.3 billion years

All biological reactions within human cells depend on enzymes. Their power as catalysts enables biological reactions to occur usually in milliseconds. But how slowly would these reactions proceed spontaneously, in the absence of enzymes - minutes, hours, days? And why even pose the question?

12 Nov 2008

Compound found that blocks SARS virus

A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the disease.

12 Nov 2008

XDR-TB declining in the U.S.

A new report suggests that the number of cases of extensively drug-resistant tuberculosis (XDR-TB) in the U.S. has declined in the past fifteen years, but new cases continue to be reported, according to the study published in the November 12 issue of JAMA.

11 Nov 2008

Astragalus root plant chemical used to fight HIV

Like other kinds of cells, immune cells lose the ability to divide as they age because a part of their chromosomes known as a telomere becomes progressively shorter with cell division.

11 Nov 2008

Researchers describe how cells recycle protein waste

Garbage collectors are important for removing trash; without them waste accumulates and can quickly become a health hazard.

11 Nov 2008

Protein called TIM-3 turns off HIV-fighting T cells

In HIV-infected patients the body's immune system is unable to fight off the virus.

11 Nov 2008

Cells exhausted from fighting HIV infection can be rescued

Researchers at the University of Toronto and the University of California, San Francisco, have revealed new hope for HIV treatment with the discovery of a way to 'rescue' immune cells that are exhausted from fighting off HIV infection.

11 Nov 2008

One in ten patients harmed in Australian hospitals

Researchers from the University of New South Wales (UNSW) plan to tackle underlying problems in Australia's health system which harm in one in ten hospital patients each year.

10 Nov 2008

T-cell-based strategy for HIV-1 vaccines still viable option

The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520.

10 Nov 2008